Hubbry Logo
ImmunogenImmunogenMain
Open search
Immunogen
Community hub
Immunogen
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Immunogen
Immunogen
Immunogen
View on Wikipedia
from Wikipedia

An immunogen is any substance that generates B-cell (humoral/antibody) and/or T-cell (cellular) adaptive immune responses upon exposure to a host organism.[1][2] Immunogens that generate antibodies are called antigens ("antibody-generating").[2] Immunogens that generate antibodies are directly bound by host antibodies and lead to the selective expansion of antigen-specific B-cells. Immunogens that generate T-cells are indirectly bound by host T-cells after processing and presentation by host antigen-presenting cells.[3]

An immunogen can be defined as a complete antigen which is composed of the macromolecular carrier and epitopes (determinants) that can induce immune response.[4]

An explicit example is a hapten. Haptens are low-molecular-weight compounds that may be bound by antibodies, but cannot elicit an immune response. Consequently, the haptens themselves are nonimmunogenic and they cannot evoke an immune response until they bind with a larger carrier immunogenic molecule. The hapten-carrier complex, unlike free hapten, can act as an immunogen and can induce an immune response.[5]

Until 1959, the terms immunogen and antigen were not distinguished.[6]

Used carrier proteins

[edit]
It is copper-containing respiratory protein, isolated from keyhole limpets (Megathura crenulata). Because of its evolutionary distance from mammals, high molecular weight and complex structure it is usually immunogenic in vertebrate animals.[7]
(also blue carrier immunogenic orotein) It is alternative to KLH isolated from Concholepas concholepas. It has the similar immunogenic properties as KLH but better solubility and therefore better flexibility.[8]
It is from the blood sera of cows and has similarly immunogenic properties as KLH or CCH. The cationized form of BSA (cBSA) is highly positively charged protein with significantly increased immunogenicity. This change possesses a greater number of possible conjugated antigens to the protein.[9]
Also known as egg albumin, OVA is the main protein (60-75%) found in hen egg white. OVA is soluble in dimethyl sulfoxide (DMSO), which enables the conjugation of haptens that are not soluble in aqueous buffers. The immune response can be enhanced using an adjuvant injected together with the immunogen.[10]

Immunological adjuvants

[edit]

An adjuvant (from Latin adiuvare – to help) is any substance, distinct from antigen, which enhances immune response by various mechanisms: recruiting of professional antigen-presenting cells (APCs) to the site of antigen exposure; increasing the delivery of antigens by delayed/slow release (depot generation); immunomodulation by cytokine production (selection of Th1 or Th2 response); inducing T-cell response (prolonged exposure of peptide-MHC complexes [signal 1] and stimulation of expression of T-cell-activating co-stimulators [signal 2] on the APCs' surface) and targeting (e. g. carbohydrate adjuvants which target lectin receptors on APCs). Adjuvants have been used as additives to improve vaccine efficiency since the 1920s. Generally, administration of adjuvants is used both in experimental immunology and in clinical settings to ensure a high quality/quantity memory-enhanced antibody response, where antigens must be prepared and delivered in a fashion that maximizes production of a specific immune response. Among commonly used adjuvants are complete and incomplete Freund's adjuvant and solutions of aluminum hydroxide or aluminum phosphate.[11][12]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Immunogen

View on Grokipedia
from Grokipedia
An immunogen is any substance capable of eliciting an adaptive , including the activation of B cells for production and T cells for cellular immunity, upon exposure to a host organism. While all immunogens are antigens—molecules that can bind to specific immune receptors such as or T-cell receptors—not all antigens qualify as immunogens, as the latter must actively provoke a detectable immune reaction rather than merely binding. This distinction is critical in , where depends on the substance's ability to be processed and presented by antigen-presenting cells to trigger both innate and adaptive defenses. The of a substance is influenced by several key factors, including its molecular size (typically greater than 10 for effective recognition), chemical complexity (such as proteins or with diverse epitopes), and degree of foreignness relative to the host's self-proteins, which enhances binding to () molecules and T-cell engagement. Proteins remain the most potent immunogens due to their capacity to stimulate robust T-cell help, essential for B-cell maturation and long-term immunological memory, whereas smaller molecules like haptens require conjugation to a carrier protein to become immunogenic. Additional enhancers, such as adjuvants (e.g., or microbial components), often boost by promoting uptake, , and co-stimulatory signals from antigen-presenting cells. In practical contexts, immunogens underpin vaccine development, diagnostic assays, and therapeutic strategies, where their ability to induce protective immunity against pathogens or tumors is harnessed while minimizing unwanted reactions like allergenicity. For instance, viral proteins or bacterial serve as immunogens in to mimic and prime the without causing disease. Understanding immunogen properties also informs , where engineered immunogens target cancer cells by eliciting targeted cytotoxic responses.

Definition and Fundamentals

Definition

An immunogen is any substance capable of eliciting an adaptive , specifically stimulating through B-cell activation and production, and/or cellular immunity via T-cell responses, upon exposure to a host organism. This response involves the recognition and processing of the immunogen by immune cells, leading to the generation of memory cells that provide long-term protection against subsequent encounters with the same substance. All immunogens qualify as antigens because they can bind specifically to antibodies or T-cell receptors, but the reverse is not true: immunogens are distinguished by their ability to actively induce an rather than merely being recognized by pre-existing immune components. This active induction requires the immunogen to engage the in a way that triggers proliferation and differentiation of lymphocytes, often dependent on the host's immune status and the substance's inherent properties. Immunogens are typically complete antigens comprising a macromolecular carrier—such as a large protein or —and multiple epitopes, which are specific molecular regions recognized by immune receptors to facilitate effective immune activation. These epitopes provide the structural basis for immune specificity, allowing the immunogen to interact with a diverse repertoire of B- and T-cell receptors. Common examples of immunogenic substances include proteins like viral envelope glycoproteins, which potently trigger both antibody and T-cell responses; polysaccharides from bacterial capsules, which primarily elicit humoral immunity; and nucleic acids such as viral DNA or RNA, which can stimulate innate and adaptive pathways when recognized as foreign. An antigen is defined as any molecule or molecular fragment that can bind specifically to an antibody or be presented by a major histocompatibility complex (MHC) molecule to a T-cell receptor, without necessarily eliciting an immune response. In contrast, an immunogen is a type of antigen that possesses the additional capacity to provoke a humoral or cell-mediated immune response, thereby activating the adaptive immune system. All immunogens are thus antigens by virtue of their binding properties, but not all antigens qualify as immunogens, as the latter requires the induction of immunological memory and effector functions. Historically, the terms "" and "" were used interchangeably until around 1959, when the distinction emerged to emphasize the difference between mere recognition and active response induction. This separation reflected advancing understanding in , highlighting that while antigens can be tolerogenic or non-stimulatory in certain contexts, immunogens consistently drive protective immunity. Haptens represent another related category, consisting of low-molecular-weight compounds (typically under 1,000 Da) that exhibit antigenicity but lack on their own. These molecules become immunogenic only when covalently conjugated to a larger carrier protein, which provides the necessary structural complexity to engage immune cells effectively. For instance, penicillin acts as a , binding to host proteins to form allergenic complexes that trigger IgE-mediated reactions, but it does not induce responses in isolation. Conversely, complete proteins such as serve as full immunogens, capable of independently eliciting robust production due to their size and conformational epitopes.

Properties and Characteristics

Structural Requirements

For a substance to function as an immunogen, it must possess a sufficiently large molecular size, typically exceeding 10,000 Da, which enables efficient uptake via by antigen-presenting cells such as dendritic cells and macrophages, facilitating subsequent and presentation to T cells. Smaller molecules below this threshold, like simple haptens, generally fail to elicit robust responses on their own and require conjugation to larger carriers for . This size requirement correlates with the physical ability of immune cells to internalize and degrade the immunogen, as larger structures are more readily recognized and handled within endocytic pathways. The immunogenic potential is further enhanced by the presence of multiple epitopes—specific regions recognized by B-cell or T-cell receptors—distributed across the carrier molecule, which promotes multivalent cross-linking of receptors and amplifies intracellular signaling cascades. This multiepitope arrangement allows for simultaneous engagement of multiple immune cells, leading to stronger activation and proliferation compared to single-epitope structures. In proteins, for instance, overlapping B-cell epitopes on the surface can drive polyclonal responses by providing diverse binding sites that sustain prolonged immune interactions. Chemical properties of the immunogen, including hydrophilicity, net charge, and conformational stability, critically influence immune recognition and accessibility of . Hydrophilic regions, rich in polar and charged , are preferentially exposed on the molecular surface, making them ideal for B-cell formation and binding due to favorable interactions in aqueous environments. Charged residues contribute to electrostatic attractions with immune receptors, while conformational stability preserves the native three-dimensional structure essential for maintaining integrity during processing and . in these features can lead to unfolding and reduced , as seen in denatured proteins that lose accessible . A fundamental structural requisite is the principle of foreignness, whereby the immunogen must be perceived as non-self to trigger an rather than inducing tolerance. Self-like structures are ignored or suppressed by the host's to prevent , whereas greater phylogenetic distance from host proteins heightens recognition as foreign, thereby promoting activation of naive lymphocytes. This non-self attribute ensures that the immunogen's epitopes are not subject to central or mechanisms, allowing for effective initiation of adaptive immunity.

Factors Influencing Immunogenicity

The immunogenicity of an is modulated by a complex interplay of host, immunogen-specific, and environmental variables that can either enhance or suppress the magnitude and quality of the . These factors determine whether an elicits a robust adaptive immunity or induces tolerance, with implications for and therapeutic outcomes. Understanding these influences is crucial for optimizing immunogenic strategies, as they interact dynamically to shape recognition and activation. Host factors play a pivotal role in determining an individual's responsiveness to immunogens. Genetic background, particularly variations in (MHC) haplotypes, governs efficiency and T-cell repertoire diversity, thereby influencing susceptibility to specific pathogens and responses. Age-related diminishes thymic output and alters profiles, leading to reduced titers and cellular immunity in older populations. Nutritional status affects immune competence by modulating nutrient-sensing pathways and availability, such as and , which support maturation and T-cell proliferation; deficiencies exacerbate . Overall immune competence, influenced by comorbidities like or chronic diseases, further attenuates responses by promoting chronic low-grade that exhausts effector cells. Immunogen-related factors, including dose, route of administration, and exposure frequency, directly impact the threshold for immune activation versus tolerance. Optimal dosing balances sufficient without overwhelming the system, as low doses may favor tolerogenic responses through regulatory T-cell dominance, while high doses can induce anergy. The alters antigen uptake and processing; subcutaneous or intramuscular delivery often yields higher than intravenous due to enhanced recruitment and prolonged antigen exposure at lymphoid sites. Frequency of exposure modulates response durability, with spaced administrations promoting formation, whereas frequent dosing risks exhaustion and diminished recall responses. Environmental influences, such as concurrent infections and the host , can either amplify or dampen by altering immune . Active infections compete for immune resources and skew environments toward Th1 or Th2 biases, potentially reducing responses to unrelated immunogens. The gut shapes systemic immunity through production and training of , with linked to impaired vaccine responses via reduced IgA and T-helper function. Quantitative aspects of immunogenicity hinge on epitope density and binding affinity thresholds that dictate effective T- and B-cell engagement. High epitope density on an immunogen surface enhances multivalent interactions with antigen receptors, lowering the activation threshold and boosting overall response magnitude. Affinity thresholds, often defined by MHC-peptide dissociation constants below 500 nM or percentile ranks under 1% in predictive models, ensure sufficient stability for immune surveillance, with subthreshold affinities failing to sustain clonal expansion. Larger structural size of the immunogen can indirectly support higher epitope density, contributing to these quantitative effects.

Types of Immunogens

Natural Immunogens

Natural immunogens are substances derived directly from foreign biological organisms with minimal processing, such as pathogens, that elicit an . These include a diverse array of biomolecules found in viruses, , parasites, and other microbes, which serve as targets for both innate and adaptive immunity due to their structural complexity and recognition by immune receptors. Proteins represent some of the most potent natural immunogens, owing to their ability to present multiple, complex epitopes that engage both B-cell and T-cell responses effectively. For instance, bacterial toxins like , a detoxified form of the neurotoxin produced by , induces strong production and long-lasting immunity through its diverse antigenic determinants. Polysaccharides from biological sources, such as the capsular components of like or type b, are also natural immunogens but typically elicit T-cell-independent responses that result in short-lived immunity, particularly in adults where T-cell help is needed for robust, memory-forming responses; conjugation to proteins is often required to enhance their . Lipids and nucleic acids derived from pathogens function as natural immunogens by activating pattern recognition receptors (PRRs) on innate immune cells, bridging innate responses to adaptive immunity; examples include lipopolysaccharide (LPS) lipids from Gram-negative bacteria and viral RNA/DNA recognized by Toll-like receptors (TLRs), which trigger cytokine production and subsequent antigen-specific responses. Pathogen-specific examples highlight the role of natural immunogens in infection control, such as viral envelope proteins like the (HA) of influenza virus or the (Env) of , which display conformational epitopes on the virion surface to provoke neutralizing antibodies. Similarly, parasitic surface antigens, including the SAG1 protein on Toxoplasma gondii tachyzoites, serve as key immunogens that elicit protective humoral and cellular responses against invasion.

Synthetic Immunogens

Synthetic immunogens are laboratory-engineered molecules designed to elicit targeted immune responses by mimicking or enhancing the of natural antigens, allowing for precise control over presentation and stability. These constructs address limitations of natural immunogens, such as poor or weak T-cell engagement, through or biotechnological assembly. Unlike unmodified biological entities, synthetic immunogens enable customization for specific pathogens or diseases, improving and profiles. Peptide-based immunogens consist of short sequences, typically 10-50 residues long, engineered to replicate specific B-cell or T-cell epitopes from target antigens. These peptides are synthesized chemically to ensure purity and homogeneity, targeting conserved regions like the V3 loop in HIV-1 glycopeptides or the NPNA repeats in circumsporozoite protein. To overcome the inherent instability and low of linear peptides, which are prone to rapid enzymatic degradation, multimeric forms are often employed; for instance, conjugation to scaffolds or display on virus-like particles creates repetitive arrays that enhance crosslinking and prolong serum half-life. Such designs have shown promise in clinical trials for infectious diseases, including vaccines like Multimeric-001, where multivalency boosted titers without adjuvants. Conjugate vaccines represent a of synthetic immunogen technology, involving the covalent linkage of poorly immunogenic —such as bacterial capsular —to carrier proteins like tetanus or CRM197. This conjugation transforms T-cell-independent antigens into T-cell-dependent ones, enabling formation, affinity maturation, and B-cell generation. The carrier protein is internalized by B cells, processed into peptides, and presented via to T follicular helper cells, thereby recruiting T-cell help for polysaccharide-specific responses. A seminal example is the type b (Hib) , licensed in 1987, which links the Hib capsular to diphtheria , dramatically reducing invasive Hib disease incidence in vaccinated children by over 90% through sustained production. Nanoparticle and virus-like particle (VLP) immunogens leverage self-assembling protein structures to display antigens in a multivalent, particulate format, facilitating targeted delivery to antigen-presenting cells and enhanced immune presentation. VLPs, derived from viral capsid proteins like those of or human papillomavirus, lack genetic material and thus pose no infection risk, yet their nanoscale size (10-200 nm) promotes uptake by dendritic cells via . This leads to efficient on MHC class I and II, activating both CD8+ cytotoxic T cells and CD4+ helper T cells, while surface modifications—such as attachment—enable tissue-specific targeting, for example, to the liver or mucosa. In vaccine applications, VLPs have demonstrated superior compared to soluble antigens; HPV VLPs in elicit robust neutralizing antibodies, providing long-term protection against oncogenic strains. Rational design of synthetic immunogens increasingly incorporates computational modeling to predict and optimize structures for maximal . Tools like and structural vaccinology integrate , , and simulations to engineer stable conformations, such as prefusion-stabilized viral spikes, or to graft s onto scaffolds that avoid off-target responses. For instance, reverse vaccinology analyzes genomes to select antigenic candidates, followed by machine learning-based refinement to enhance B- and T-cell exposure. These approaches have accelerated development, as seen in RSV and immunogens where computational thermostabilization improved neutralizing elicitation in preclinical models.

Mechanisms of Immune Response

B-Cell Activation

B-cell activation begins when an immunogen binds to the (BCR), a membrane-bound immunoglobulin that recognizes specific epitopes on the surface. For effective activation, the immunogen must typically present multivalent epitopes that cross-link multiple BCRs on the surface, clustering them into signaling complexes. This cross-linking initiates intracellular signaling cascades through the immunoreceptor tyrosine-based activation motifs (ITAMs) of the BCR-associated Igα and Igβ chains, recruiting kinases such as Syk and activating pathways like PI3K-Akt, which promote B-cell proliferation, survival, and differentiation. Immunogens are classified as T-dependent (TD) or T-independent () based on their ability to activate B cells with or without T-cell assistance. TD immunogens, such as proteins, require CD4+ helper T cells for full activation; after BCR cross-linking and internalization, B cells process and present immunogen-derived peptides on molecules, enabling linked recognition by cognate T cells that deliver co-stimulatory signals via CD40 ligand (CD40L) and cytokines like IL-4. In contrast, TI immunogens, including bacterial or lipopolysaccharides, directly stimulate B cells through repetitive epitopes that extensively BCRs, often amplified by co-receptors such as Toll-like receptors (TLRs), bypassing the need for T-cell help and leading to rapid but typically lower-affinity responses. Upon activation, B cells migrate to lymphoid follicles, where immunogen exposure drives (GC) formation in both TD and certain TI responses. GCs serve as dynamic microenvironments divided into dark zones for B-cell proliferation and , and light zones for antigen-driven selection on (FDCs). In TD responses, interactions with T follicular helper (Tfh) cells further support GC maintenance, while TI immunogens can induce transient GCs that nonetheless facilitate mutation and selection. This process culminates in affinity maturation, where somatic hypermutations in BCR variable regions are introduced by activation-induced cytidine deaminase (AID), and B cells with higher-affinity BCRs are positively selected through enhanced survival signals. Concurrently, class-switch recombination (CSR), also mediated by AID and directed by cytokines (e.g., IL-4 for IgG1 or IgE switching), allows B cells to shift from IgM production to other isotypes like IgG or IgA, tailoring antibody effector functions. The primary outcomes of immunogen-induced B-cell activation are the generation of high-affinity antibodies secreted by long-lived plasma cells and the establishment of memory B cells. These memory B cells, often bearing somatically mutated BCRs, persist in lymphoid tissues and , enabling rapid and enhanced secondary responses upon re-exposure to the same immunogen. In TI contexts, GC-derived memory B cells demonstrate comparable to TD responses, though with potentially reduced diversity.

T-Cell Involvement

Immunogens elicit T-cell responses primarily through processing by antigen-presenting cells (APCs), such as dendritic cells and macrophages, which internalize the immunogen, degrade it into fragments via proteasomal or lysosomal pathways, and load these onto (MHC) molecules for surface presentation. This MHC- complex is recognized by T-cell receptors (TCRs) on naïve T cells, initiating activation only when the peptide fits specifically into the MHC groove and matches the TCR specificity. APCs upregulate co-stimulatory molecules like and during this process to provide the necessary second signal for full T-cell activation, preventing anergy. CD4+ helper T cells (Th cells) are activated by immunogen-derived peptides presented on molecules, differentiating into subsets based on environments and transcription factors. Th1 cells, driven by IL-12 and T-bet, produce IFN-γ to promote activation and against intracellular pathogens. Th2 cells, induced by IL-4 and GATA3, secrete IL-4, IL-5, and IL-13 to support humoral responses and recruitment in parasitic infections. Th17 cells, stimulated by TGF-β and IL-6 via RORγt, release IL-17 and IL-22 to drive recruitment and mucosal immunity, particularly against extracellular bacteria and fungi. These subsets coordinate broader immune responses, including -mediated help to B cells for production and class switching. CD8+ cytotoxic T cells (CTLs) recognize immunogen peptides, typically from endogenous sources like viral proteins, presented on molecules expressed on nearly all nucleated cells. Upon activation via TCR engagement and , CTLs release perforin and granzymes to induce in target cells, such as virus-infected or tumor cells, thereby limiting spread. This direct killing mechanism is crucial for clearing intracellular infections and is enhanced by CD4+ T-cell-derived cytokines like IL-2. Activated T cells differentiate into memory T cells, which persist long-term in lymphoid tissues and circulation to provide rapid protection upon re-exposure to the same . Memory + and + T cells maintain through IL-7 and IL-15 signaling, retaining effector functions or quickly reacquiring them for enhanced responses. This memory formation ensures durable immunity, as seen in vaccine-induced protection against pathogens like .

Enhancement Strategies

Carrier Proteins

Carrier proteins are immunogenic macromolecules, typically large proteins, that are covalently conjugated to s—small molecules incapable of eliciting an on their own—to render them immunogenic. This conjugation forms a hapten-carrier complex that bridges humoral and cellular immunity, allowing the otherwise non-immunogenic hapten to stimulate production. The primary mechanism involves the carrier protein supplying multiple T-cell epitopes, which are recognized by helper T cells, enabling linked recognition with B-cell epitopes provided by the . This cooperative interaction, known as the carrier effect, was first demonstrated through experiments showing that secondary responses to haptens require prior priming with the same carrier, highlighting the necessity of T-B cell collaboration for effective antibody responses. Without such linkage, haptens fail to activate B cells due to the absence of T-cell help. Key properties of effective carrier proteins include high molecular weight for structural stability, abundance of conjugation sites (e.g., residues), in aqueous solutions, and a net positive charge to facilitate cellular uptake and processing. Non-mammalian origins are preferred to avoid immunological tolerance from pre-existing antibodies in mammalian hosts. For instance, cationization—replacing anionic carboxylic groups with cationic aminoethylamide groups—increases the positive charge on proteins like (BSA), thereby enhancing and altering immunoregulatory properties without compromising . Prominent examples include (KLH), a copper-containing derived from the marine Megathura crenulata, with a molecular weight of approximately 350–390 kDa per subunit and extensive that furnishes diverse T-cell epitopes. KLH's large size, complex structure, and phylogenetic distance from vertebrates confer high immunogenicity while minimizing tolerance, making it a standard for conjugation. (BSA), a 66 kDa serum protein with 59 residues ideal for chemical linkage, offers ease of conjugation and high solubility but exhibits moderate immunogenicity in mammals due to ; cationized BSA addresses this by boosting T-cell responses. Ovalbumin (OVA), a 45 kDa from chicken , serves as a model carrier in experimental owing to its well-characterized epitopes, excellent solubility, and ability to elicit robust, reproducible responses in models. Recent advancements as of 2023–2025 have introduced innovative carriers beyond traditional proteins, including virus-like particles (VLPs) and outer membrane vesicles (OMVs). For example, glycan-engineered alphavirus-like VLPs, such as those derived from , , and Venezuelan Equine Encephalitis viruses, have been developed for HIV-1 fusion immunogens. These VLPs incorporate additional glycans to mask carrier-specific epitopes, reducing off-target immune responses by up to 88% and enhancing neutralizing production against multi-clade HIV strains through sequential . OMVs, derived from bacterial outer membranes, serve as self-adjuvanted carriers in glycoconjugate vaccines, providing built-in immunostimulatory components like lipopolysaccharides to amplify T-cell help without the limitations of homology-induced tolerance in protein-based carriers. In applications, carrier proteins are indispensable for protocols to generate high-affinity antibodies against small molecules like peptides or drugs, as well as for conjugate vaccines where they link carbohydrate haptens to T-cell epitopes for enhanced B-cell . Adjuvants may complement carrier effects by amplifying non-specific responses, but carriers primarily drive antigen-specific linked recognition.

Immunological Adjuvants

Immunological adjuvants are non-antigenic substances that enhance the elicited by immunogens, thereby improving the efficacy of vaccines and immunotherapies by modulating innate immunity and promoting adaptive responses. These agents work by amplifying and stimulating immune cells without directly acting as antigens themselves. The use of adjuvants dates back to the 1920s, when aluminum salts, known as , were first employed to boost production in experimental . In the 1930s, Jules Freund developed Freund's incomplete adjuvant, a water-in-mineral oil , and Freund's complete adjuvant, which incorporated heat-killed mycobacteria to further intensify cellular immunity. These early formulations established the foundation for adjuvant use by demonstrating their ability to enhance both humoral and cellular responses to immunogens. Adjuvants exert their effects through multiple mechanisms, including the recruitment of (APCs) to the site of injection, induction of pro-inflammatory such as IL-1β and IL-6, and prolongation of exposure via depot formation at the injection site. For instance, APC recruitment facilitates greater uptake and migration to nodes, while induction promotes APC maturation and T-cell priming. The depot effect sustains availability, allowing for extended interactions with immune cells and sustained immune activation. Modern adjuvants include aluminum salts, which provide a depot effect by slowly releasing immunogens and activate the to drive IL-1β production and innate immune signaling. (TLR) agonists, such as CpG DNA motifs that target TLR9, exemplify another class by mimicking pathogen-associated molecular patterns to trigger robust responses and enhance activation. Adjuvants are classified into several types based on their physical form and . Particulate adjuvants, such as liposomes, deliver immunogens in a structured manner to improve cellular uptake by APCs and protect antigens from degradation. Soluble adjuvants, including derived from plants like Quillaja saponaria, stimulate innate immunity by forming complexes that promote membrane disruption and release. Genetic adjuvants, such as -based formulations (e.g., IL-2 or GM-CSF), encode or deliver immunomodulatory proteins to amplify T-cell responses and sustain immune memory. Recent developments as of 2024–2025 have expanded adjuvant options with emerging materials and systems. Polymer-based adjuvants, such as , alginate, , and β-glucans, offer biodegradable platforms that enhance stability, mucosal delivery, and targeted immune activation through interactions with receptors. Additionally, genetically encoded adjuvants have advanced to include and other modulators delivered via vectors, enabling precise control of immune cell trafficking and polarization for improved therapeutic outcomes in cancer and infectious vaccines. Efforts like the () adjuvant library, launched in 2025, facilitate rapid screening of adjuvant combinations to optimize responses against emerging pathogens.

Applications and Uses

Vaccine Development

Immunogens are fundamental to vaccine development, serving as the antigenic components that elicit targeted immune responses for prophylaxis against infectious diseases or in chronic infections. Prophylactic use immunogens to prime the , generating memory cells that confer long-term protection upon exposure. Therapeutic vaccines, conversely, aim to enhance waning or inadequate immunity in affected individuals. Key platforms leverage immunogens in diverse forms to optimize efficacy while ensuring safety, focusing on structural fidelity to native without inducing . Live-attenuated vaccines use weakened forms of the live as immunogens, which replicate mildly in the host to closely mimic natural infection and stimulate both humoral and cellular immunity. These vaccines are produced by adapting pathogens through in laboratory cultures to reduce while retaining . The measles, , and (MMR) vaccine, for example, contains live-attenuated viruses that induce lifelong immunity in most recipients after two doses, though it is contraindicated in immunocompromised individuals due to the risk of uncontrolled replication. This platform offers strong, durable protection but requires strict cold-chain storage to maintain viability. Inactivated or killed vaccines incorporate whole immunogens from pathogens that are chemically or physically treated (e.g., with ) to eliminate infectivity while preserving conformational epitopes for robust induction. The inactivated polio vaccine (IPV), for example, utilizes -inactivated types 1, 2, and 3, with each dose containing specified D-antigen units (40 for type 1, 8 for type 2, and 32 for type 3) to stimulate neutralizing without . This approach ensures for immunocompromised populations but may require multiple doses or adjuvants for sustained . Subunit vaccines employ purified or recombinant immunogens, isolating specific proteins to focus the response on critical s and reduce non-specific reactogenicity. The recombinant exemplifies this, comprising surface (HBsAg) produced by inserting the HBsAg into cells via technology, yielding non-infectious 22-nm particles that induce anti-HBs antibodies protective against HBV infection. Such vaccines offer precise control over dosage and purity, though they often necessitate adjuvants like aluminum to amplify immune activation. Viral vector vaccines use a modified, non-replicating (the ) to deliver genetic instructions for producing a specific in host cells, thereby presenting the in a context that elicits strong T- and B-cell responses. The , for instance, employs a recombinant adenovirus type 26 encoding the ; upon administration, host cells express the spike, which is processed and presented to trigger without causing infection. This platform combines elements of and natural , enabling robust cellular immunity, though pre-existing immunity to the may reduce in some populations. Messenger RNA (mRNA) vaccines encode immunogens within synthetic mRNA delivered via lipid nanoparticles, enabling transient in vivo expression by host cells to mimic natural infection. Post-2020 COVID-19 vaccines, including those from Pfizer-BioNTech and Moderna, encode the SARS-CoV-2 spike protein as the immunogen; upon cellular uptake, the mRNA directs ribosomal translation of the spike, which is presented on the cell surface or secreted, triggering B- and T-cell responses against the virus. This platform allows rapid adaptation to emerging threats through sequence modifications. Vaccine development faces significant challenges in harmonizing immunogen with profiles, particularly in avoiding excessive or while achieving durable protection. High can heighten reactogenicity, such as local or systemic adverse events, necessitating optimized dosing and formulations to mitigate risks without diminishing . Furthermore, viral variants pose ongoing hurdles, as mutations in immunogens like the spike can reduce neutralization, requiring iterative updates to immunogen design for cross-variant coverage.

Diagnostics and Research

Immunogens play a crucial role in laboratory diagnostics by serving as the basis for generating polyclonal or monoclonal antibodies that enable the detection of specific antigens in immunoassays such as . In these assays, animals are immunized with target immunogens to produce high-affinity antibodies, which are then immobilized or used as detectors to bind and quantify analytes in clinical samples, facilitating identification for diseases like infections or cancers. In immunological research, model immunogens like ovalbumin (OVA) are widely employed in to investigate mechanisms of and . For instance, mice immunized with OVA in various formulations help model allergic responses or tolerance induction, allowing researchers to dissect pathways involved in preventing autoimmune diseases by analyzing T-cell and B-cell dynamics post-immunization. Immunogens are essential for producing therapeutic monoclonal antibodies through techniques like hybridoma fusion and libraries. In hybridoma production, animals are with specific immunogens to activate B cells, which are then fused with myeloma cells to create immortalized lines secreting monoclonal antibodies for therapeutic use against targets such as cytokines or tumor antigens. complements this by presenting antibody fragments on bacteriophages, selected against immobilized immunogens to isolate high-specificity clones without animal immunization. As research tools, hapten-carrier conjugates enable precise by linking small, non-immunogenic haptens—such as fragments—to carrier proteins like (KLH), rendering them immunogenic and eliciting antibodies that target defined epitopes on larger antigens. This approach allows fine-grained analysis of antibody-antigen interactions, aiding in the identification of immunodominant regions for diagnostic or therapeutic development.

Historical Development

Early Concepts

The foundations of the concept of immunogens trace back to the late 18th century, when developed the first in 1796 by inoculating individuals with material, which implicitly harnessed an immunogenic substance to confer protective immunity without the use of specific terminology. Jenner's approach demonstrated that exposure to a related, milder could induce resistance to a more virulent one, laying early groundwork for understanding substances capable of triggering immune responses, though the mechanisms remained unexplored at the time. In the 1890s, advanced these ideas through his work on , particularly in collaboration with Shibasaburo Kitasato, where they developed the first effective serum therapy against and by immunizing animals with sublethal doses of bacterial toxins to produce neutralizing antibodies. This approach highlighted the role of toxins as inducers of protective immune responses, establishing a link between specific substances and the elicitation of production, which formed a cornerstone of early . Prior to 1959, the terms "" and "" were used synonymously in to describe substances that could induce an , with ""—coined in 1899 by Ladislav Deutsch to refer to bacterial products eliciting —encompassing both recognition by the and the ability to provoke it. The term "" itself first appeared around 1959 to more precisely denote agents capable of generating immunity. During the , Karl Landsteiner's experiments with small molecules, such as conjugated to proteins, revealed that these "" could not independently induce antibody production but required attachment to a carrier protein to become immunogenic, underscoring the need for structural complexity in immune induction.

Key Milestones

In 1959, the term "" was first used in immunological to formally distinguish substances capable of inducing an active from mere antigens, which only bind to antibodies or sensitized cells without necessarily triggering immunity. This emphasis on response induction, as opposed to simple recognition, laid the groundwork for more precise studies on factors like molecular size, foreignness, and dosage. During the and , the development of s represented a major breakthrough in enhancing the of antigens, particularly for protecting young children against bacterial infections. Researchers demonstrated that linking bacterial capsular to carrier proteins, such as diphtheria toxoid, converted poorly immunogenic T-independent antigens into T-dependent ones, eliciting stronger and longer-lasting responses with memory. Pioneering work in this era focused on pathogens like type b (Hib), with the first licensed (HibTITER) approved in 1987, dramatically reducing invasive disease incidence. Similar conjugation strategies were applied to meningococcal starting in the late , leading to experimental vaccines against serogroups A and C that improved efficacy in infants compared to plain versions. The saw significant innovations in adjuvants and recombinant immunogens, enabling the creation of safer and more targeted vaccines without live pathogens. Adjuvants like aluminum salts were refined, and novel formulations such as oil-in-water emulsions (e.g., MF59, approved in 1997 for vaccines) were introduced to boost and production, thereby enhancing both humoral and cellular immunity. Concurrently, technology advanced immunogen design, allowing production of viral proteins in heterologous systems; a key example was the development of human papillomavirus (HPV) vaccines using self-assembling virus-like particles (VLPs) from the L1 protein, first demonstrated in preclinical studies in 1991 and culminating in the licensure of in 2006, which prevents by inducing neutralizing antibodies. In the , the advent of mRNA-based immunogens revolutionized vaccine technology, particularly during the 2020 . Synthetic mRNA encoding the , encapsulated in lipid nanoparticles for cellular delivery and translation, elicited robust neutralizing and T-cell responses without . The Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 vaccines received in December 2020, demonstrating over 90% in phase 3 trials and marking the first widespread use of immunogens in humans. This approach expanded the repertoire of synthetic immunogens, paving the way for rapid adaptation to emerging pathogens. The foundational work on mRNA modifications enabling these vaccines was recognized with the in Physiology or Medicine in 2023, awarded to and .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK10755/
  2. https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_%28Kaiser%29/Unit_6%253A_Adaptive_Immunity/12%253A_Introduction_to_Adaptive_Immunity/12.2%253A_Antigens_and_Epitopes
  3. https://bio.libretexts.org/Bookshelves/[Microbiology](/page/Microbiology)/Microbiology_%28Kaiser%29/Unit_6%253A_Adaptive_Immunity/12%253A_Introduction_to_Adaptive_Immunity/12.2%253A__and_Epitopes
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123983/
  5. https://www.pacificimmunology.com/resources/antigens/antigens-vs-immunogens/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7127059/
  7. https://www.sciencedirect.com/topics/chemistry/immunogen
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7123983/
  9. https://academic.oup.com/immunohorizons/article/6/5/312/7816771
  10. https://www.sciencedirect.com/topics/immunology-and-microbiology/hapten
  11. https://pubmed.ncbi.nlm.nih.gov/9506435/
  12. https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learning-center/antibodies-resource-library/antibody-methods/antibody-production-immunogen-preparation.html
  13. https://www2.nau.edu/~fpm/immunology/lectures/Chapter03.pdf
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7927956/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9883670/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5490637/
  17. https://d-scholarship.pitt.edu/13094/1/Structural.pdf
  18. https://www.utep.edu/eerael/immunology.htm
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7652061/
  20. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-017-1207-1
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6431125/
  22. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.665968/full
  23. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1655819/full
  24. https://www.fda.gov/media/85017/download
  25. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7848667/
  27. https://www.nature.com/articles/s41422-020-0332-7
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC11927049/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3505629/
  30. https://www.researchgate.net/figure/C-50-threshold-of-epitopes-derived-from-the-IEDB-The-cumulative-epitope-distribution-is_fig3_258282313
  31. https://help.iedb.org/hc/en-us/articles/114094151811-Selecting-thresholds-cut-offs-for-MHC-class-I-and-II-binding-predictions
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC10336728/
  33. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-21-tetanus.html
  34. https://www.pnas.org/doi/10.1073/pnas.1819612116
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4364189/
  36. https://www.nature.com/articles/s41392-021-00687-0
  37. https://www.nature.com/articles/ni.1863
  38. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.638573/full
  39. https://parasitesandvectors.biomedcentral.com/articles/10.1186/1756-3305-7-180
  40. https://pubs.acs.org/doi/10.1021/acs.chemrev.9b00472
  41. https://publications.aap.org/pediatrics/article/84/2/386/55885/Haemophilus-influenzae-Type-b-Conjugate-Vaccines
  42. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-021-00806-7
  43. https://pubs.acs.org/doi/10.1021/acs.jctc.3c00513
  44. https://www.ncbi.nlm.nih.gov/books/NBK27142/
  45. https://doi.org/10.1016/j.cell.2019.03.016
  46. https://doi.org/10.1084/jem.20210527
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC6314495/
  48. https://www.ncbi.nlm.nih.gov/books/NBK26926/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6300129/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7663252/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3312336/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC8324560/
  53. https://www.ncbi.nlm.nih.gov/books/NBK27101/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7151904/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5371741/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC2680212/
  57. https://www.sciencedirect.com/topics/immunology-and-microbiology/hapten-carrier-complex
  58. https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830010103
  59. https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830010104
  60. https://pubmed.ncbi.nlm.nih.gov/2433331/
  61. https://pubmed.ncbi.nlm.nih.gov/10544506/
  62. https://www.taconic.com/products/phenotypic-data-packages/comprehensive/ovalbumin-challenge
  63. https://www.nature.com/articles/s41541-025-01288-6
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9983441/
  65. https://www.nature.com/articles/s41573-021-00163-y
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10356842/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4494348/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC5724967/
  69. https://onlinelibrary.wiley.com/doi/10.1155/2016/1459394
  70. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00114/full
  71. https://www.sciencedirect.com/science/article/pii/S0264410X17301688
  72. https://www.mdpi.com/2076-393X/2/2/252
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3147301/
  74. https://www.nature.com/articles/s41392-023-01557-7
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC7348637/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC9147349/
  77. https://www.sciencedirect.com/science/article/abs/pii/S0378517325010178
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC12180328/
  79. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-1-principles-of-vaccination.html
  80. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm
  81. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-10-hepatitis-b.html
  82. https://www.hhs.gov/immunization/basics/types/index.html
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC7918810/
  84. https://www.nature.com/articles/s12276-023-00999-x
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC9761649/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8948777/
  87. https://www.nature.com/articles/s41541-023-00793-w
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC6636315/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC2579966/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC9040095/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC7485114/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC145282/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC10311653/
  94. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2011.00021/full
  95. https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-smallpox-vaccination
  96. https://www.nobelprize.org/prizes/medicine/1901/behring/article/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC5347343/
  98. https://www.merriam-webster.com/dictionary/immunogen
  99. https://www.sciencedirect.com/topics/medicine-and-dentistry/hapten
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC1905528/
  101. https://www.sciencedirect.com/science/article/abs/pii/S0264410X10006080
  102. https://www.nobelprize.org/prizes/medicine/2023/press-release/
Add your contribution
Related Hubs
User Avatar
No comments yet.